Skip to main content
Top
Published in: Annals of Hematology 2/2019

01-02-2019 | Original Article

Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort

Authors: Lata Rani, Ajay Gogia, Vishwajeet Singh, Lalit Kumar, Atul Sharma, Gurvinder Kaur, Ritu Gupta

Published in: Annals of Hematology | Issue 2/2019

Login to get access

Abstract

Prognostic indices combining several clinical and laboratory parameters have been proposed for prognostication in chronic lymphocytic leukemia (CLL). Recently, international consortium on CLL proposed an international prognostic index (CLL-IPI) integrating clinical, molecular, and genetic parameters. The present study was designed to evaluate the reproducibility of CLL-IPI in Indian CLL cohort. The prognostic ability of CLL-IPI in terms of overall survival (OS) and time to first treatment (TTFT) was investigated in treatment-naive CLL patients and also compared with other existing prognostic scores. For assigning scores, clinical and laboratory details were obtained from medical records, and IGHV gene mutation status, β2-microglobulin levels, and copy number variations were determined using c-DNA, ELISA, and multiplex ligation-dependent probe amplification (MLPA), respectively. The scores were generated as per the weighted grades assigned to each variable involved in score categorization. The predictive value of prognostic models was assessed and compared using Harrell’s C-index and Akaike’s information criterion (AIC). Stratification of patients according to CLL-IPI yielded significant differences in terms of OS and TTFT (p < 0.001). Comparative assessment of scores for OS suggested better performance of CLL-IPI (C = 0.64, AIC = 740) followed by Barcelona–Brno (C = 0.61, AIC = 754) and MDACC score (C = 0.59, AIC = 759). Comparison of predictive value of prognostic scores for TTFT illustrated better performance of CLL-IPI (C = 0.72, AIC = 726) followed by Barcelona–Brno (C = 0.68, AIC = 743), modified GCLLSG (C = 0.66, AIC = 744), and O-CLL1 index (C = 0.55, AIC = 773). The results suggest better performance of CLL-IPI in terms of both OS and TTFT as compared to other available scores in our cohort.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M (2007) Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109:4679–4685CrossRefPubMed Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M (2007) Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109:4679–4685CrossRefPubMed
2.
go back to reference Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer S, Döhner H, Jäger U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek M (2014) Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 124:49–62CrossRefPubMedPubMedCentral Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer S, Döhner H, Jäger U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek M (2014) Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 124:49–62CrossRefPubMedPubMedCentral
4.
go back to reference Molica S, Giannarelli D, Mirabelli R, Levato L, Russo A, Linardi M, Gentile M, Morabito F (2016) Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model. Eur J Haematol 96:72–77CrossRefPubMed Molica S, Giannarelli D, Mirabelli R, Levato L, Russo A, Linardi M, Gentile M, Morabito F (2016) Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model. Eur J Haematol 96:72–77CrossRefPubMed
5.
go back to reference Gentile M, Shanafelt TD, Cutrona G, Molica S, Tripepi G, Alvarez I, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, Todoerti K, Matis S, Musolino C, Fabris S, Vigna E, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Arcari A, Federico M, Mannina D, Recchia AG, Neri A, Kay NE, Ferrarini M, Morabito F (2016) A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. Leukemia 30:1440–1443CrossRefPubMed Gentile M, Shanafelt TD, Cutrona G, Molica S, Tripepi G, Alvarez I, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, Todoerti K, Matis S, Musolino C, Fabris S, Vigna E, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Arcari A, Federico M, Mannina D, Recchia AG, Neri A, Kay NE, Ferrarini M, Morabito F (2016) A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. Leukemia 30:1440–1443CrossRefPubMed
6.
go back to reference International CLL-IPI working group (2016) An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 17:779–790CrossRef International CLL-IPI working group (2016) An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 17:779–790CrossRef
7.
go back to reference Molica S, Shanafelt TD, Giannarelli D, Gentile M, Mirabelli R, Cutrona G, Levato L, Di Renzo N, Di Raimondo F, Musolino C, Angrilli F, Famà A, Recchia AG, Chaffee KG, Neri A, Kay NE, Ferrarini M, Morabito F (2016) The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: independent validation in a prospective cohort of early stage patients. Am J Hematol 91:1090–1095CrossRefPubMedPubMedCentral Molica S, Shanafelt TD, Giannarelli D, Gentile M, Mirabelli R, Cutrona G, Levato L, Di Renzo N, Di Raimondo F, Musolino C, Angrilli F, Famà A, Recchia AG, Chaffee KG, Neri A, Kay NE, Ferrarini M, Morabito F (2016) The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: independent validation in a prospective cohort of early stage patients. Am J Hematol 91:1090–1095CrossRefPubMedPubMedCentral
8.
go back to reference Gentile M, Shanafelt TD, Rossi D, Laurenti L, Mauro FR, Molica S, Cutrona G, Uccello G, Campanelli M, Vigna E, Tripepi G, Chaffee KG, Parikh SA, Bossio S, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foà R, Morabito F (2016) Validation of the CLLIPI and comparison with the MDACC prognostic index: analysis of 1364 newly diagnosed patients. Blood 128:2093–2095CrossRefPubMedPubMedCentral Gentile M, Shanafelt TD, Rossi D, Laurenti L, Mauro FR, Molica S, Cutrona G, Uccello G, Campanelli M, Vigna E, Tripepi G, Chaffee KG, Parikh SA, Bossio S, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foà R, Morabito F (2016) Validation of the CLLIPI and comparison with the MDACC prognostic index: analysis of 1364 newly diagnosed patients. Blood 128:2093–2095CrossRefPubMedPubMedCentral
9.
go back to reference Delgado J, Doubek M, Baumann T, Kotaskova J, Molica S, Mozas P, Rivas-Delgado A, Morabito F, Pospisilova S, Montserrat E (2017) Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol 92:375–380CrossRefPubMed Delgado J, Doubek M, Baumann T, Kotaskova J, Molica S, Mozas P, Rivas-Delgado A, Morabito F, Pospisilova S, Montserrat E (2017) Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol 92:375–380CrossRefPubMed
10.
go back to reference Gentile M, Shanafelt TD, Mauro FR, Laurenti L, Rossi D, Molica S, Vincelli I, Cutrona G, Uccello G, Pepe S, Vigna E, Tripepi G, Chaffee KG, Parikh SA, Bossio S, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foà R, Morabito F (2018) Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: analysis of 1299 newly diagnosed cases. Am J Hematol. 93:E35–E37CrossRefPubMed Gentile M, Shanafelt TD, Mauro FR, Laurenti L, Rossi D, Molica S, Vincelli I, Cutrona G, Uccello G, Pepe S, Vigna E, Tripepi G, Chaffee KG, Parikh SA, Bossio S, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foà R, Morabito F (2018) Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: analysis of 1299 newly diagnosed cases. Am J Hematol. 93:E35–E37CrossRefPubMed
11.
go back to reference Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ (2008) International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446–5456CrossRefPubMedPubMedCentral Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ (2008) International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446–5456CrossRefPubMedPubMedCentral
12.
go back to reference Rani L, Mathur N, Gogia A, Vishnubhatla S, Kumar L, Sharma A, Dube D, Kaur P, Gupta R (2016) Immunoglobulin heavy chain variable region gene repertoire and B-cell receptor stereotypes in Indian patients with chronic lymphocytic leukemia. Leuk Lymphoma. 57:2389–2400CrossRefPubMed Rani L, Mathur N, Gogia A, Vishnubhatla S, Kumar L, Sharma A, Dube D, Kaur P, Gupta R (2016) Immunoglobulin heavy chain variable region gene repertoire and B-cell receptor stereotypes in Indian patients with chronic lymphocytic leukemia. Leuk Lymphoma. 57:2389–2400CrossRefPubMed
13.
go back to reference Rai K (1987) A critical analysis of staging in CLL. In: Gale R, Rai K (eds) Chronic lymphocytic leukemia: recent progress and future direction. Alan R Liss, New York (NY), p 253 Rai K (1987) A critical analysis of staging in CLL. In: Gale R, Rai K (eds) Chronic lymphocytic leukemia: recent progress and future direction. Alan R Liss, New York (NY), p 253
14.
go back to reference Shanafelt TD, Jenkins G, Call TG, Zent CS, Slager S, Bowen DA, Schwager S, Hanson CA, Jelinek DF, Kay NE (2009) Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 115:363–372CrossRefPubMedPubMedCentral Shanafelt TD, Jenkins G, Call TG, Zent CS, Slager S, Bowen DA, Schwager S, Hanson CA, Jelinek DF, Kay NE (2009) Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 115:363–372CrossRefPubMedPubMedCentral
15.
go back to reference Bulian P, Tarnani M, Rossi D, Forconi F, Del Poeta G, Bertoni F, Zucca E, Montillo M, Pozzato G, Deaglio S, D'Arena G, Efremov D, Marasca R, Lauria F, Gattei V, Gaidano G, Laurenti L (2011) Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. Hematol Oncol 29:91–99CrossRefPubMed Bulian P, Tarnani M, Rossi D, Forconi F, Del Poeta G, Bertoni F, Zucca E, Montillo M, Pozzato G, Deaglio S, D'Arena G, Efremov D, Marasca R, Lauria F, Gattei V, Gaidano G, Laurenti L (2011) Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. Hematol Oncol 29:91–99CrossRefPubMed
16.
go back to reference Gentile M, Mauro FR, Rossi D, Vincelli I, Tripepi G, Recchia AG, De Stefano L, Campanelli M, Giannarelli D, Bossio S, Morabito L, Vigna E, Gaidano G, Foà R, Morabito F (2014) Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. Br J Haematol 167:224–232CrossRefPubMed Gentile M, Mauro FR, Rossi D, Vincelli I, Tripepi G, Recchia AG, De Stefano L, Campanelli M, Giannarelli D, Bossio S, Morabito L, Vigna E, Gaidano G, Foà R, Morabito F (2014) Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. Br J Haematol 167:224–232CrossRefPubMed
17.
go back to reference Gogia A, Sharma A, Raina V, Kumar L, Vishnubhatla S, Gupta R, Kumar R (2012) Assessment of 285 cases of chronic lymphocytic leukemia seen at single large tertiary center in Northern India. Leuk Lymphoma 53:1961–1965CrossRefPubMed Gogia A, Sharma A, Raina V, Kumar L, Vishnubhatla S, Gupta R, Kumar R (2012) Assessment of 285 cases of chronic lymphocytic leukemia seen at single large tertiary center in Northern India. Leuk Lymphoma 53:1961–1965CrossRefPubMed
18.
go back to reference Molica S, Giannarelli D, Levato L, Mirabelli R, Gentile M, Morabito F (2017) Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI). Leuk Lymphoma 58:1736–1739CrossRefPubMed Molica S, Giannarelli D, Levato L, Mirabelli R, Gentile M, Morabito F (2017) Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI). Leuk Lymphoma 58:1736–1739CrossRefPubMed
19.
go back to reference Molica S, Giannarelli D, Mirabelli R, Levato L, Kay N, Shanafelt TD (2018) Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis. Blood 131:365–368CrossRefPubMed Molica S, Giannarelli D, Mirabelli R, Levato L, Kay N, Shanafelt TD (2018) Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis. Blood 131:365–368CrossRefPubMed
20.
go back to reference Alhourani E, Rincic M, Othman MA, Pohle B, Schlie C, Glaser A, Liehr T (2014) Comprehensive chronic lymphocytic leukemia diagnostics by combined multiplex ligation dependent probe amplification (MLPA) and interphase fluorescence in situ hybridization (iFISH). Mol Cytogenet 7:79CrossRefPubMedPubMedCentral Alhourani E, Rincic M, Othman MA, Pohle B, Schlie C, Glaser A, Liehr T (2014) Comprehensive chronic lymphocytic leukemia diagnostics by combined multiplex ligation dependent probe amplification (MLPA) and interphase fluorescence in situ hybridization (iFISH). Mol Cytogenet 7:79CrossRefPubMedPubMedCentral
Metadata
Title
Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort
Authors
Lata Rani
Ajay Gogia
Vishwajeet Singh
Lalit Kumar
Atul Sharma
Gurvinder Kaur
Ritu Gupta
Publication date
01-02-2019
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 2/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-018-3525-0

Other articles of this Issue 2/2019

Annals of Hematology 2/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine